383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study

Komal Jhaveri, R. Jeselsohn, X. Cynthia, Elgene Lim, Kan Yonemori, Erika Hamilton, K. Harnden, S-A. Im, T. Beck, Sarah Sammons, Manali Bhave, Peter A. Kaufman, C. Saura Manich, Tarek Meniawy, Francesca Bacchion, Roohi Ismail‐Khan, Yuelin Li, Shawn T. Estrem, Bella Nguyen, M. Beeram